{
    "nct_id": "NCT05168202",
    "official_title": "A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes",
    "inclusion_criteria": "• Eastern Cooperative Oncology Group Performance Status of 0 to 2\n\nFor Parts A & B:\n\n* Relapsed or refractory (R/R) acute myeloid leukemia (AML) as defined by the 2016 WHO Classification\n* R/R myelodysplastic syndromes (MDS) as defined by the 2016 WHO Classification with intermediate, high or very high risk by Revised International Prognostic Scoring System (IPSS-R)\n\nFor Part C:\n\n• Treatment-naïve (TN) (ie, previously untreated) MDS as defined by the 2016 WHO Classification with intermediate, high or very high risk by IPSS-R\n\nFor Part D:\n\n• TN AML as defined by the 2016 WHO Classification, including secondary AML and therapy-related AML in participants who are ineligible (IE) for intensive chemotherapy (IC) and allogeneic hematopoietic stem cell transplant (HSCT)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Acute promyelocytic leukemia\n* Immediately life-threatening, severe complications of leukemia such as disseminated/uncontrolled infection, uncontrolled bleeding, and/or uncontrolled disseminated intravascular coagulation\n* Participants who have received prior treatment with a CD47 or SIRPα targeting agent\n* Participant is on chronic systemic immunosuppressive therapy or corticosteroids\n* Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half-lives or 4 weeks prior to starting study treatment, whichever is shorter (relapsed or refractory participants only).\n* Any condition including, active or uncontrolled infection, or the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study\n* Pregnant or nursing participants.\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}